Does Rallies show 13F holders for ZNTL?

Yes. Rallies tracks hedge fund and 13F ownership data for ZNTL, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ZNTL research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ZNTL. It does not provide personalized investment advice.

ZNTL (Zentalis Pharmaceuticals, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Zentalis Pharmaceuticals, Inc. Common Stock (ZNTL) is a publicly traded Healthcare sector company. As of May 21, 2026, ZNTL trades at $3.68 with a market cap of $258.41M and a P/E ratio of -1.92. ZNTL moved +4.52% today. Year to date, ZNTL is +170.80%; over the trailing twelve months it is +189.84%. Its 52-week range spans $1.01 to $6.95. Analyst consensus is buy with an average price target of $7.00. Rallies surfaces ZNTL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ZNTL stock?

Hedge funds tracked by Rallies that own ZNTL include Matrix Capital and Panagora Asset. The latest tracked quarter is Sep 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Zentalis Pharmaceuticals, Inc. Common Stock.

ZNTL Key Metrics

Key financial metrics for ZNTL
Metric	Value
Price	$3.68
Market Cap	$258.41M
P/E Ratio	-1.92
EPS	$-1.91
Dividend Yield	0.00%
52-Week High	$6.95
52-Week Low	$1.01
Volume	6.87K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-137.06M
Gross Margin	0.00%

Top Hedge Funds Holding ZNTL

Matrix Capital holds 13.96M shares of ZNTL, changed +0.00% as of Sep 30, 2025.
Panagora Asset holds 139.69K shares of ZNTL, changed +61.23% as of Mar 31, 2026.

Latest ZNTL News

Zentalis Selects 400mg QD 5:2 Dose, Q1 Cash at $212M — May 12, 2026
Zentalis Doses First Patient in Phase 3 ASPENOVA Trial for Cyclin E1 Ovarian Cancer — May 5, 2026
Zentalis to Present Azenosertib-Paclitaxel Phase 1b Data for Platinum-Resistant Ovarian Cancer — Apr 21, 2026
Azenosertib Induces 87.5% Complete Responses in TNBC Models; Ovarian Time To Next Treatment at 13.2 Months — Apr 17, 2026
Zentalis Selects 400mg QD 5:2 Dose After Superior DENALI Part 2a Results — Apr 9, 2026

Recent ZNTL Insider Trades

Vultaggio Vincent sold 6.89K (~$16.70K) on Feb 10, 2026.
Bruns Ingmar sold 335 (~$801.622) on Feb 9, 2026.
Vultaggio Vincent sold 3.38K (~$8.09K) on Feb 9, 2026.

ZNTL Analyst Consensus

7 analysts cover ZNTL: 0 strong buy, 4 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $7.00.

Common questions about ZNTL

Who owns ZNTL stock?: Hedge funds tracked by Rallies that own ZNTL include Matrix Capital and Panagora Asset. The latest tracked quarter is Sep 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Zentalis Pharmaceuticals, Inc. Common Stock.
Does Rallies show 13F holders for ZNTL?: Yes. Rallies tracks hedge fund and 13F ownership data for ZNTL, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ZNTL research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ZNTL. It does not provide personalized investment advice.